Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

Patient Noncompliance Clinical Trial

— CAE-L  

Official title:

A Prospective Trial of Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAE-L) in Individuals With Schizophrenia or Schizoaffective Disorder at Risk for Treatment Non-adherence and for Homelessness

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01152697
• Other study ID #: Reuter-L1473
• Status: Completed
• Phase: N/A
• First received: June 24, 2010
• Last updated: December 8, 2014
• Start date: June 2010
• Est. completion date: August 2012

Study information

• Verified date: December 2014
• Source: University Hospital Case Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%. Inadequate adherence is associated with poor outcomes such as relapse, homelessness, hospitalization, and increased health care costs. Studies have shown a direct correlation between non-adherence and rates of relapse in schizophrenia; on average, non-adherent patients have a risk of relapse that is 3.7 times greater than their adherent counterparts. A major obstacle to good outcomes in the maintenance treatment of patients with severe mental illness is difficulty with medication routines on an on-going basis. For this reason, long-acting injectable antipsychotic medication is a particularly attractive treatment option for populations with schizophrenia and schizoaffective disorder, although it is unlikely that medication treatment alone is likely to modify long-term attitudes and behaviors.

This prospective study is a pilot analysis of a combined approach which merges a psychosocial intervention to optimize treatment attitudes towards psychotropic medication (CAE) and long-acting injectable antipsychotic medication (L) in recently homeless individuals with schizophrenia or schizoaffective disorder who are known to have on-going difficulties with treatment non-adherence. It is expected that this combined approach (CAE-L) will improve illness outcomes among the most vulnerable of populations with schizophrenia or schizoaffective disorder.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: August 2012
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Individuals age 18 years old and older with schizophrenia or schizoaffective disorder as confirmed by the Mini International Psychiatric Inventory (MINI).

2. Individuals who are currently or have been recently homeless (within the past 12 months) as per the official federal definition of homelessness.

3. Known to have medication treatment adherence (20% or more missed medications in past week or past month) problems as identified by the Treatment Routines Questionnaire patient or clinician versions (TRQ-P/TRQ-C).

4. Ability to be rated on psychiatric rating scales.

5. Willingness to take long-acting injectable medication.

6. Currently receiving treatment at a Community Mental Health Clinic (CMHC) or another mental health treatment provider who is able to provide continuity of care during and after study participation.

7. Able to provide written, informed consent to study participation.

8. Women of child-bearing potential must be utilizing reliable, medically-accepted methods of birth control.

Exclusion Criteria:

1. Known resistance or intolerance to haloperidol or haloperidol decanoate.

2. Medical contraindication to haloperidol or haloperidol decanoate.

3. Individuals on long-acting injectable antipsychotic medication immediately prior to study enrollment.

4. Prior or current treatment with clozapine.

5. Concurrent medical condition or psychiatric illness, which in the opinion of the research psychiatrist, would interfere with the patient's ability to participate in the trial.

6. Current substance dependence.

7. High risk of harm to self or others.

8. Female who is currently pregnant or breastfeeding.

9. Individual who is already in permanent and supported housing that includes comprehensive mental health services (e.g. Housing First).

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Patient Noncompliance

Intervention

Drug:
• haloperidol decanoate
Drug is in in injectable form and will be administered approximately every four weeks through Week 25 of the study. A participant may continue on the drug after Week 25 at the discretion of his or her treating psychiatrist. Dosage is per package insert or at the discretion of the psychiatrist.
• haloperidol
Drug will be administered in oral form to participants not already taking oral haloperidol and then transitioned to the injectable version. Dosage and frequency is at the discretion of the psychiatrist.

Behavioral:
• Customized Adherence Enhancement
CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).

Locations

Country	Name	City	State
United States	University Hosptials	Cleveland	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital Case Medical Center	Case Western Reserve University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Days Homeless Out of the Previous 6 Months as Measured at 25 Weeks	Subjects will be asked how many days they have been homeless	Baseline-25 weeks	No
Primary	Change From Baseline in Treatment Adherence Score as Measured at 25 Weeks	A total treatment adherence score will calculated as a proportion of medications taken as reported from the participant, and evidenced by pill counts and documented medication injections.	Baseline-25 weeks	No
Primary	Change From Baseline in Adherence Attitude Score as Measured by the Drug Attitude Inventory (DAI) at 25 Weeks	Ten item inventory taken by the participant with a Scale Range: 0-10. Higher scores indicate improved outcomes.	Baseline-25 weeks	No
Primary	Change From Baseline in Treatment Adherence Behavior Score as Measured by the Morisky Medication Rating Scale at 25 Weeks	Four item inventory taken by participant with Scale Range: 0-4. Lower scores indicate improved outcomes.	Baseline-25 weeks	No
Primary	Change From Baseline in Adherence Attitude Score as Measured by the Attitude Toward Medication Questionnaire (AMQ) at 25 Weeks	Nineteen item inventory taken by the participant with Scale Range:0-19. Lower scores indicate improved outcomes.	Baseline-25 weeks	No
Secondary	Frequency of Health Resource Use Throughout Months 10, 11, and 12	The frequency of health resource use will be measured through interview of the participant.	Month 1-3, Month 10-12	No
Secondary	Change in Serious Mental Illness Severity Score as Measured by the Brief Psychiatric Rating Scale (BPRS) at 25 Weeks	The BPRS, developed by Overall and Gorham (1962), is a widely used, relatively brief scale that measures major psychotic and non-psychotic symptoms in individuals with SMI. The 18-item BPRS is well-validated and is perhaps the most researched instrument in psychiatry. Reliability coefficients are reported to be in the range of 0.56-0.87.; Scale Range: 18-126 Lower scores represent improved outcomes.	Baseline-25 weeks	No
Secondary	Change in Global Psychopathology as Measured by the Clinical Global Impressions (CGI) at 25 Weeks	Global psychopathology will be measured with the Clinical Global Impressions (CGI) (Guy 1976) a widely used scale which evaluates illness severity on a 1 to 7 point continuum. Severity of illness ratings on the CGI have reported reliability scores ranging from 0.41-0.66 (Guy 1976) Lower scores indicate improved outcomes. Higher scores indicate worse outcomes.; Illness scale: 1 - 7 (1 = Normal/not at all ill ; 7 = Among the most extremely ill patients) Global improvement scale: 1 - 7 (1 = Very much improved ; 7 = Very much worse)	Baseline-25 weeks	No
Secondary	Change in Social and Occupational Functioning Scale (SOFAS) as Measured at 25 Weeks	Life and Work Functional status will be evaluated using the Social and Occupational Functioning Scale (SOFAS), which is derived from the GAF (Global Assessment of Functioning). The GAF is a 100-point single-item scale which measures global functioning of psychiatric patients and is widely utilized in clinical studies involving Seriously Mentally Ill patients (Jones 1995). The reliability of the GAF ranges from 0.62-0.82. Higher scores indicate improved outcomes.	Baseline-25 weeks	No
Secondary	Treatment Satisfaction as Measured by the Participant Acceptability and Satisfaction Questionnaire at 25 Weeks	Satisfaction will be measured by a seven item inventory taken by the participant.; Scale ranges from 1 (Strongly Agree) to 5 (Strongly Disagree). Lower scores indicate better outcomes, while higher scores indicate worse outcomes. The highest possible score is 35.	25 weeks	No
Secondary	Change in Schizophrenia and Schizoaffective Disorder Symptom Severity Scale as Measured by the Positive and Negative Syndrome Scale (PANSS) at 25 Weeks	The PANSS (Kay, Fiszbein, & Opler 1987) was created to assess both the positive and negative symptoms of schizophrenia such as hallucinations and emotional withdrawal, respectively. The scale rates 30 symptoms on a scale from 1 (absent) to 7 (extreme) and has been shown to limit bias between the assessment of positive and negative symptoms, providing a broad but balanced spectrum of the illness.; There are three subscales: positive symptoms, negative symptoms, general psychopathology. Potential responses to Items on all subscales range from 1 (absent) to 7 (extreme). Lower scores indicate lower symptoms and, therefore, better outcomes. Higher scores indicate more presence of symptoms and, therefore, worse outcomes.; Subscales are combined to produce a total score, which is summed from all of the subscales. Lower total scores indicate lower symptoms and, therefore, better outcomes. Higher total scores indicate more presence of symptoms and, therefore, worse outcomes.	Baseline-25 weeks	No
Secondary	Frequency of Health Resource Use in the Past 3 Months as Measured at 25 Weeks	The frequency of health resource use will be measured through interview of the participant.	25 weeks	No
Secondary	Global Psychopathology as Measured by the Clinical Global Impressions (CGI) at 12 Months	Global psychopathology will be measured with the Clinical Global Impressions (CGI) (Guy 1976) a widely used scale which evaluates illness severity on a 1 to 7 point continuum. Severity of illness ratings on the CGI have reported reliability scores ranging from 0.41-0.66 (Guy 1976) Lower scores indicate improved outcomes. Higher scores indicate worse outcomes.; Illness scale: 1 - 7 (1 = Normal/not at all ill ; 7 = Among the most extremely ill patients) Global improvement scale: 1 - 7 (1 = Very much improved ; 7 = Very much worse)	12 months	No
Secondary	Change in Social and Occupational Functioning Scale (SOFAS) as Measured at 12 Months	Life and Work Functional status will be evaluated using the Social and Occupational Functioning Scale (SOFAS), which is derived from the GAF. The GAF is a 100-point single-item scale which measures global functioning of psychiatric patients and is widely utilized in clinical studies involving Seriously Mentally Ill patients (Jones 1995). The reliability of the GAF ranges from 0.62-0.82. Higher scores indicate improved outcomes.	Baseline-12 months	No
Secondary	Treatment Satisfaction as Measured by the Participant Acceptability and Satisfaction Questionnaire at 12 Months	Satisfaction will be measured by a seven item inventory taken by the participant.; Scale ranges from 1 (Strongly Agree) to 5 (Strongly Disagree). Lower scores indicate better outcomes, while higher scores indicate worse outcomes. The highest possible score is 35.	12 months	No
Secondary	Days Homeless Out of the Previous 6 Months as Measured at 12 Months	Subjects will be asked how many days they have been homeless	12 months	No
Secondary	Treatment Adherence Score as Measured at 12 Months	A total treatment adherence score will calculated as a proportion of medications taken as reported from the participant, and evidenced by pill counts and documented medication injections.	12 months	No
Secondary	Adherence Attitude Score as Measured by the Drug Attitude Inventory (DAI) at 12 Months	Ten item inventory taken by the participant with a Scale Range: 0-10. Higher scores indicate improved outcomes.	12 months	No
Secondary	Treatment Adherence Behavior Score as Measured by the Morisky Medication Rating Scale at 12 Months	Four item inventory taken by participant with Scale Range: 0-4. Lower scores indicate better outcomes.	12 months	No
Secondary	Adherence Attitude Score as Measured by the Attitude Toward Medication Questionnaire (AMQ) at 12 Months	Nineteen item inventory taken by the participant with Scale Range:0-19. Lower scores indicate improved outcomes.	12 months	No